Hantavirus pulmonary syndrome: At the crossroads

A. S. Khan, J. C. Young

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

The initial identification in 1993 of hantavirus pulmonary syndrome as a novel, highly fatal respiratory illness among American Indians in the southwestern USA in 1993 opened the window to the recognition of a well-established pan-American zoonosis with a myriad of causative viruses and rodent vectors, although all are New World hantaviruses among New World sigmodontine rodents. The clinical spectrum of symptoms has also been expanded to include asymptomatic infection through to fulminant hemorrhagic fever. Although the use of ribavirin, an antiviral drug, was disappointing in an early, open-labeled trial, early detection and supportive care is much better refined. However, much work remains in probing the pathogenesis of this syndrome to help define and explore therapeutic options and the mechanism of person-to-person transmission with Andes virus, one of the viruses that cause hantavirus pulmonary syndrome. Current remote sensing efforts and longitudinal ecologic investigations need to be expanded in order to focus prevention efforts better.

Original languageEnglish (US)
Pages (from-to)205-209
Number of pages5
JournalCurrent Opinion in Infectious Diseases
Volume14
Issue number2
DOIs
StatePublished - Jan 1 2001

Fingerprint

Hantavirus Pulmonary Syndrome
Hantavirus
Rodentia
Viruses
Asymptomatic Infections
North American Indians
Ribavirin
Zoonoses
Antiviral Agents
Fever
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Hantavirus pulmonary syndrome : At the crossroads. / Khan, A. S.; Young, J. C.

In: Current Opinion in Infectious Diseases, Vol. 14, No. 2, 01.01.2001, p. 205-209.

Research output: Contribution to journalReview article

@article{e279b4e447b44a85aab0810df8070b54,
title = "Hantavirus pulmonary syndrome: At the crossroads",
abstract = "The initial identification in 1993 of hantavirus pulmonary syndrome as a novel, highly fatal respiratory illness among American Indians in the southwestern USA in 1993 opened the window to the recognition of a well-established pan-American zoonosis with a myriad of causative viruses and rodent vectors, although all are New World hantaviruses among New World sigmodontine rodents. The clinical spectrum of symptoms has also been expanded to include asymptomatic infection through to fulminant hemorrhagic fever. Although the use of ribavirin, an antiviral drug, was disappointing in an early, open-labeled trial, early detection and supportive care is much better refined. However, much work remains in probing the pathogenesis of this syndrome to help define and explore therapeutic options and the mechanism of person-to-person transmission with Andes virus, one of the viruses that cause hantavirus pulmonary syndrome. Current remote sensing efforts and longitudinal ecologic investigations need to be expanded in order to focus prevention efforts better.",
author = "Khan, {A. S.} and Young, {J. C.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1097/00001432-200104000-00016",
language = "English (US)",
volume = "14",
pages = "205--209",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Hantavirus pulmonary syndrome

T2 - At the crossroads

AU - Khan, A. S.

AU - Young, J. C.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The initial identification in 1993 of hantavirus pulmonary syndrome as a novel, highly fatal respiratory illness among American Indians in the southwestern USA in 1993 opened the window to the recognition of a well-established pan-American zoonosis with a myriad of causative viruses and rodent vectors, although all are New World hantaviruses among New World sigmodontine rodents. The clinical spectrum of symptoms has also been expanded to include asymptomatic infection through to fulminant hemorrhagic fever. Although the use of ribavirin, an antiviral drug, was disappointing in an early, open-labeled trial, early detection and supportive care is much better refined. However, much work remains in probing the pathogenesis of this syndrome to help define and explore therapeutic options and the mechanism of person-to-person transmission with Andes virus, one of the viruses that cause hantavirus pulmonary syndrome. Current remote sensing efforts and longitudinal ecologic investigations need to be expanded in order to focus prevention efforts better.

AB - The initial identification in 1993 of hantavirus pulmonary syndrome as a novel, highly fatal respiratory illness among American Indians in the southwestern USA in 1993 opened the window to the recognition of a well-established pan-American zoonosis with a myriad of causative viruses and rodent vectors, although all are New World hantaviruses among New World sigmodontine rodents. The clinical spectrum of symptoms has also been expanded to include asymptomatic infection through to fulminant hemorrhagic fever. Although the use of ribavirin, an antiviral drug, was disappointing in an early, open-labeled trial, early detection and supportive care is much better refined. However, much work remains in probing the pathogenesis of this syndrome to help define and explore therapeutic options and the mechanism of person-to-person transmission with Andes virus, one of the viruses that cause hantavirus pulmonary syndrome. Current remote sensing efforts and longitudinal ecologic investigations need to be expanded in order to focus prevention efforts better.

UR - http://www.scopus.com/inward/record.url?scp=0035080477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035080477&partnerID=8YFLogxK

U2 - 10.1097/00001432-200104000-00016

DO - 10.1097/00001432-200104000-00016

M3 - Review article

C2 - 11979134

AN - SCOPUS:0035080477

VL - 14

SP - 205

EP - 209

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 2

ER -